Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through…
Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus, to enable unprecedented precision in targeting aggressive cancersIQ Capital, Cancer Research Horizons, National Brain Tumor Society, AIN Ventures and Old College Capital now also investors in...
Nasdaq GlobeNewswire
18/11/2024
LIfT BioSciences expands into Ireland for manufacturing & clinical operations
LIfT BioSciences expands into Ireland for manufacturing & clinical operationsLondon,18 November 2024– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech company preparing to start clinical trials for its first-in-class allogeneic innate cell therapy, today announces the expansion of its manufacturing and clinical operations with the opening of a new subsidiary in Galway, Ireland,Eolaíocht Bhitheach LIfT Teoranta. This expansion marks a major milestone for...
Nasdaq GlobeNewswire
18/11/2024
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first…
"This certification will allow us to extend the reach of our innovative diagnostic solutions," said Jill German, Head of Pathology Lab at Roche Diagnostics. "The early exemption approval in Germany and Austria highlighted the urgent need for this test. Now, clinicians across Europe can access a critical tool to quickly identify ovarian cancer patients who may be eligible for targeted therapy. By enabling more precise and personalised treatment decisions, we hope this may help…
PR Newswire
18/11/2024
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with…
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2Aarhus, Denmark, 18 November 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces that it has dosed the first Charcot-Marie-Tooth (CMT) disease patient in its Phase 2a clinical trial of NMD670 followingFDA IND clearance in June 2024. The first patient was dosed under the...
Nasdaq GlobeNewswire
18/11/2024
Bylvay® (odevixibat) data shows sustained improvement in severe itch and serum…
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024PARIS, FRANCE, 18 November, 2024Ipsen (Euronext: IPN; ADR: IPSEY) today announced data at the American Association for the Study of Liver Diseases (AASLD) assessing the long-term efficacy and safety of patients treated with Bylvay ®from two Phase III open-label extension studies: late-breaking abstract (#5045) on PEDFIC 2 in Progressive Familial...
Nasdaq GlobeNewswire
18/11/2024
Press Release: Sequana Medical Announces Strong 24-Month Results from POSEIDON…
Sequana Medical Announces Strong 24-Month Resultsfrom POSEIDON Study at AASLD The Liver Meeting® in San Diego;US PMA alfapump approval expected before end of Q1 2025 alfapump was very effective in control of ascites, virtually eliminating the need for large volume paracentesis (LVP) long term Key POSEIDON investigators report alfapump is safe and effective tool for patients requiring refractory ascites management for over six monthsOverall survival of 62% at two years in...
Nasdaq GlobeNewswire
18/11/2024
SoniVie Ltd., Appoints Veteran Medtech Executive Raymond W. Cohen as Chairman of…
Cohen is retiring from Axonics following the close of its $3.7 billion sale to Boston Scientific Corporation (NYSE: BSX). Cohen is retiring from Axonics following the close of its$3.7 billionsale to Boston Scientific Corporation (NYSE: BSX). Prior to Axonics, Cohen was the CEO of Vessix Vascular, Inc. (privately held) which developed a catheter based renal denervation system that was acquired by BSX in late 2012. Tomaso Zambelli, CEO of SoniVie, said "We look forward to benefiting...
PR Newswire
18/11/2024
KFSHRC Introduces Pioneering Virtual Pathology Services in Madinah
Reduces diagnostic turnaround times from a week to just one day RIYADH, Saudi Arabia, Nov.17, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) has unveiled its state-of-the-art Virtual Pathology Service at the Madinah branch, revolutionizing the field of anatomical pathology through advanced digital technologies. This service dramatically enhances the speed, accuracy, and accessibility of diagnostics by eliminating the need for physical slide...
Nasdaq GlobeNewswire
17/11/2024
BMC Showcases Latest Sleep and Respiratory Healthcare Solutions at MEDICA 2024
Additionally, they introduced new product, the CoughSync device, which enables non-invasive clearance of airway secretions by simulating a natural cough in patients undergoing invasive ventilation. Additionally, they introduced new product, the CoughSync device, which enables non-invasive clearance of airway secretions by simulating a natural cough in patients undergoing invasive ventilation. During the exhibition, BMC's team assembled to highlight its innovative PAP Link Digital Health...
PR Newswire
16/11/2024
DermRays Black Friday Event Offers Year's Biggest Savings and Industry…
It's essential to clarify the long-term goals of laser hair removal. Technically, it is a process of "laser hair reduction" rather than complete "removal," as some hair regrowth is normal over time. Even with consistent treatments, new hair from dormant follicles may appear after one to three years. At-home laser devices offer a manageable, convenient skincare routine, giving lasting, visible results in a way that's easier, faster, and more affordable than traditional methods…
PR Newswire
16/11/2024
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
Toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC);Toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (ESCC). In UK, toripalimab is the first and only drug for the treatment of NPC and the only...
Nasdaq GlobeNewswire
16/11/2024
d'Alba: Korea's Best-Kept Beauty Secret Set to Capture the Global Spotlight
While their domestic success is clear, d'Alba remains an under-the-radar name globally. Among those familiar with Korean beauty trends, d'Alba's white truffle-infused skincare is something of a well-kept secret, recognized by those closely attuned to K-beauty. With Korean consumers embracing the brand wholeheartedly, d'Alba is setting its sights on a new goal: making an international breakthrough. Wanting to bring the same excitement and exceptional skincare experience to beauty lovers…
PR Newswire
16/11/2024
Inventiva will present data from the final analysis of the Phase 2 study…
Data will be presented on Monday, November 18 thas a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego.LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination...
Nasdaq GlobeNewswire
15/11/2024
Global Hard Empty Capsule Market Forecast to Expand at a CAGR of 4.6% by 2030 -…
Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-29K7959/Global_and_China_Hard_Empty_Capsule_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-29K7959/Global_and_China_Hard_Empty_Capsule_Market Major Factors Driving the Growth of Hard Empty Capsule Market: The hard empty capsule market is experiencing steady growth, driven by demand across pharmaceutical, nutraceutical, and healthcare sectors. Key factors include the...
PR Newswire
15/11/2024
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in…
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 2024 and in the U.K. in October 2024PARIS, FRANCE, 15 November 2024Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ®(elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE ®study at the...
Nasdaq GlobeNewswire
15/11/2024
Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2% CAGR |…
Browse in-depth TOC on "Gene Editing Market" Browse in-depth TOC on "Gene Editing Market" 636 - Tables 65 - Figures 497 - Pages Based on Offerings,the market is divided into products and services segments. The products segment accounted for the largest share of the gene editing market in 2023. The large share of products is majorly due to the reagents, kits, and other consumables that are used in CRISPR, TALEN, ZFN and other gene editing technologies for applications such...
PR Newswire
15/11/2024
Healthcare leaders gather at House of Commons to discuss productivity-boosting…
With £2bn pledged to help digitise the NHS and bring down waiting lists, such time-saving tech is high on healthcare's agenda. Trust Chief Executive Matthew Hopkins introduced the session, which was hosted by David Burton-Sampson, MP for Southend West and Leigh, and saw technology strategists and users share their experiences of digitising vital healthcare operations. With £2bn pledged to help digitise the NHS and bring down waiting lists, such time-saving tech is high on healthcare's agenda...
PR Newswire
15/11/2024
Endo Announces Agreement for Paladin Pharma to Commercialize Wynzora® Cream in…
"Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora® Cream in Canada," said Jesper J. Lange, Chief Executive Officer, MC2 Therapeutics. "The agreement aligns with our strategy to make Wynzora® Cream available to as many patients suffering from plaque psoriasis as possible globally." "Paladin has an experienced and dedicated team, and we're pleased to work with them to introduce Wynzora ®Cream inCanada," saidJesper…
PR Newswire
15/11/2024
Navamedic ASA: Amendments to loan agreements with Observe Medical ASA
Navamedic has agreed to the following amendments to the two loan agreements: Navamedic has agreed to the following amendments to the two loan agreements: Navamedic has agreed to convertNOK 16,354,815.20of Loan 1 into shares in Observe Medical ASA at a subscription price ofNOK 0.40per share, provided that Observe Medical completes its contemplated subsequent offering at a subscription price ofNOK 0,40with gross proceeds of at leastNOK 1.500.000. In total 40,887,038 new shares...
PR Newswire
15/11/2024
Plastic Injection Molding Machine Market worth $14.78 billion by 2030 -…
Browse in-depth TOC on "Plastic Injection Molding Machine Market" Browse in-depth TOC on "Plastic Injection Molding Machine Market" 308 – Tables 55 – Figures 264 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72063702 The all-electric machine type segment is the fastest growing segment, in terms of value, of the global plastic injection molding machine market during the forecast period. The all-electric machine type segment is...
PR Newswire
15/11/2024
EUBP welcomes the inclusion of soil-biodegradable products in the Fertilising…
The FPR sets high requirements in terms of environmental safety. European Bioplastics (EUBP) welcomes the inclusion of soil-biodegradable mulch films, coating agents, and water retention polymers in the FPR and the key role given to existing standards concerning the biodegradation of mulch films in soil. The newly defined biodegradability criteria are strict but scientifically sound and will fully demonstrate that certified soil-biodegradable mulch films are environmentally safe while...
Nasdaq GlobeNewswire
15/11/2024
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option…
Numab to receive R&D funding for the preclinical development of ND081Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global development up to clinical POC HORGEN, Switzerland and TOKYO, Nov.15, 2024(GLOBE NEWSWIRE) -- Numab Therapeutics AG(“Numab”), a clinical stage biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, and Kaken Pharmaceutical Co...
Nasdaq GlobeNewswire
15/11/2024
International Cancer Organizations Present Collaborative Work During Oncology…
"NCCN is honored to participate in this important meeting," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "China is one of the top three countries in the world in terms of number of registered users for our website and downloads of NCCN Guidelines. We are grateful that our evidence-based expert consensus-driven recommendations are being utilized to guide and improve care for people with cancer throughout China and all of Asia." "NCCN is honored to participate in…
PR Newswire
15/11/2024
Aino Health AB (publ): interim report january-september 2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Aino reveals the main reasons for absence at workJanuary – September 2024 Net sales were KSEK 17 941 (17 605)Profit/loss after financial items was KSEK -6 464 (-6 812)Earnings per share were SEK-0,1 (-0,2)July – September 2024Net sales were KSEK 5 712 (5 633)Profit/loss after financial items was KSEK -1 504 (-1 215)Earnings...
Nasdaq GlobeNewswire
15/11/2024
Altri Comunicati
